跳至主要内容
临床试验/NCT06174389
NCT06174389招募中不适用

Physiological Changes Underlying the Weight Loss Plateau in Human

University of Washington2 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2023年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
90
试验地点
2
主要终点
Change in fMRI BOLD signal

研究概览

简要总结

Behavioral weight loss programs for obesity can result in weight loss and health benefits. However, behavioral weight loss often stops despite efforts to continue losing weight, this can be called an involuntarily weight loss plateau. This study investigates changes in metabolism and/or the brain that contribute to the occurrence of an involuntary weight loss plateau.

详细描述

Participants will be asked to enroll for 18-months. Each participant will complete 3 in-person study visits, then participate an a 6-month weight loss program delivered remotely. Some participants may be invited to complete 3 additional in-person visits. Study Visit activities include questionnaires, blood draws, brain MRIs, body measurement and dual energy x-ray absorptiometry (DXA) scan for body composition measurement, a breathing test, and biopsies of muscle and fat tissue. Each participant will be provided a fitness tracker and body weight scale to use throughout the study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •BMI 30.0 - 50.0 kg/m2
  • •Able to attend study intervention classes and study visits/assessments
  • •Independently living with access to food preparation facilities

排除标准

  • •Current smoker or regular use of nicotine containing products and/or cannabis
  • •Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use
  • •Known cognitive impairments or h/o stroke
  • •Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%))
  • •Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate
  • •Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding
  • •Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants
  • •History of bariatric surgery
  • •History of eating disorder
  • •Current participation in a formal weight loss program
  • •Prior or current participation in a research study involving weight loss
  • •Weight-reduced by >10% within past year
  • •Weight > 330 pounds (MRI limit)
  • •Allergy or intolerance to or unwillingness to consume study foods provided at visit
  • •MRI contraindication (e.g., implanted metal, claustrophobia)
  • •Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures
  • •Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate

研究组 & 干预措施

Behavioral Weight Loss

Experimental

Participants will undergo a behavioral weight loss program.

干预措施: Behavioral Weight Loss Program (Behavioral)

结局指标

主要结局

Change in fMRI BOLD signal

时间窗: From baseline to a weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).

fMRI BOLD signal to visual food cues within a priori brain regions of interest pre and post consuming a standardized meal. Meal-induced change will be calculated by post-pre meal BOLD signal.

Change in maximal respiratory capacity (oxygen consumption rate) in peripheral blood mononuclear cells

时间窗: From baseline to active weight loss (at least 21 days of weight loss equivalent or greater than 0.5 pounds per week) and from baseline to weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).

Mitochondrial maximal respiratory capacity will be measured in fasting samples from peripheral blood mononuclear cells.

Entry into involuntary weight loss plateau

时间窗: throughout 18-month enrollment

binary outcome (Y/N) and time from baseline

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ellen Schur, MD, MS

Professor: School of Medicine

University of Washington

研究点 (2)

Loading locations...

相似试验